Efek Samping Obat Gefitinib pada Pasien Kanker Paru dengan Epidermal Growth Factor Receptor (EGFR) Mutasi Positif

Ni Putu Parwatininghati, Fita Rahmawati, I Gede Ketut Sajinadiyasa
10.25077/jsfk.10.2.238-247.2023

Abstrak


Deteksi mutasi Epidermal Growth Factor Receptor (EGFR) pada pasien kanker paru akan membantu dalam pemilihan targeted therapy yaitu gefitinib. Studi mengenai evaluasi profil keamanan gefitinib di Indonesia sangat terbatas sehingga penelitian ini bertujuan untuk mengetahui efek samping obat hematologi dan non hematologi dari gefitinib pada pasien kanker paru dengan EGFR mutasi positif. Rancangan penelitian adalah observasional cross sectional. Data sekunder diambil melalui rekam medis tahun 2020 sampai 2022 pada 44 pasien. Probabilitas efek samping obat diukur dengan Naranjo Adverse Drug Reaction Probability Scale dan tingkat keparahan efek samping obat dinilai menggunakan Common Terminology Criteria for Adverse Events (CTCAE). Hasil penelitian menunjukkan efek samping hematologi yang paling sering muncul adalah anemia grade 1 pada 18 pasien (40.91%). Pada efek samping non hematologi, rash grade 2 mendominasi pada 20 pasien (45.46%), 14 pasien (31.82%) mengalami peningkatan serum transaminase grade 1, diare grade 1 terjadi pada 5 pasien (11.36%) dan mual muntah grade 2 dialami oleh 3 pasien (6.82%). Total 36 pasien (81.82%) mengalami efek samping dengan 19 kejadian termasuk kategori possible dan 17 kejadian termasuk kategori probable. Efek samping yang muncul bersifat ringan, dapat ditangani dan tidak kumulatif. Tidak didapatkan penyesuaian dosis atau penghentian penggunaan obat yang disebabkan oleh efek samping obat.


Kata Kunci


kanker paru, Epidermal Growth Factor Receptor (EGFR), gefitinib, efek samping obat.

Teks Lengkap:

PDF

Referensi


. PDPI. Kanker Paru. Pedoman Diagnosis dan Penatalaksanaan di Indones. 2013;19. Available from: http://klikpdpi.com/konsensus/konsensus-kankerparu/kankerparu.pdf

. Lukeman JM. What Is Lung Cancer? Perspect Lung Cancer. 2015;30–40. https://doi.org/10.1159/000400400

. WHO. International Agency for Research on Cancer. 2021;858:2020–1.

. Dewi A, Thabrany H, Satrya A, Gemala Chairunnisa Puteri, Fattah RA, Novitasari D. Kanker Paling Mematikan Di Indonesia : Apa Saja Yang Telah Kita Atasi. Pkjs-Ui. 2021;1–29. Available from: https://pkjsui.org/wp-content/uploads/2021/05/PKJS-UI_Dialog-Pemangku-Kepentingan-Kanker-Paru.pdf

. Thomas P, Vincent B, George C, Joshua JM, Pavithran K, Vijayan & M. A Comparative Study on Erlotinib & Gefitinib Therapy in Non-Small Cell Lung Carcinoma Patients. Indian J Med Res. 2019;150:67–72. https://doi.org/10.4103/ijmr.IJMR

. Jamaluddin M. Efikasi Dan Toksisiti Erlotinib/Gefitinib Sebagai Terapi Lini Kedua Pada Pasien Kanker Paru Jenis Karsinoma Bukan Sel Kecil. 2015;1–95.

. Aw DCW, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. Asia Pac J Clin Oncol. 2018;14(1):23–31. https://doi.org/10.1111/ajco.12687

. Kozuki T. Skin problems and EGFR-tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46(4):291–8. https://doi.org/10.1093/jjco/hyv207

. Umara AF, Wulandari ISM, Supriadi E, Rukmi DK, Silalahi LE, Malisa N, et al. Keperawatan Medikal Bedah Sistem Respirasi. Yayasan Kita Menulis; 2021.

. Sun YQ, Chen Y, Langhammer A, Skorpen F, Wu C, Mai XM. Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: The HUNT study. Eur Respir J. 2017;50(4):7–10. https://doi.org/10.1183/13993003.00824-2017

. Du Y, Cui X, Sidorenkov G, Groen HJM, Vliegenthart R, Heuvelmans MA, et al. Lung cancer occurrence attributable to passive smoking among never smokers in China: A systematic review and meta-analysis. Transl Lung Cancer Res. 2020;9(2):204–17. https://doi.org/10.21037/tlcr.2020.02.11

. Kementerian Kesehatan Republik Indonesia. Buku_Pedoman_Pengendalian_Faktor_Risiko_Kanker_Paru_Tahun_2018.pdf. 2018.

. Siddiqui IA, Sanna V, Ahmad N, Sechi M, Mukhtar H. Resveratrol nanoformulation for cancer prevention and therapy. Ann N Y Acad Sci. 2015;1348(1):20–31. https://doi.org/10.1111/nyas.12811

. Buana I, Harahap DA. Asbestos, Radon dan Polusi Udara sebagai Faktor Resiko Kanker Paru pada Perempuan Bukan Perokok. 2022;8(1).

. Menkes RI. Pedoman Nasional Pelayanan Kedokteran Kanker Paru. 2017;

. Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The Risk for Anemia with Targeted Therapies for Solid Tumors. Oncologist. 2012;17(5):715–24. https://doi.org/10.1634/theoncologist.2012-0024

. Liu H bing, Wu Y, Lv T feng, Yao Y wen, Xiao Y ying, Yuan D mei, et al. Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS One. 2013;8(1). https://doi.org/10.1371/journal.pone.0055128

. Araya T, Kasahara K, Demura Y, Matsuoka H, Nishitsuji M, Nishi K. Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer. Lung Cancer. 2013;80(3):344–6. https://doi.org/10.1016/j.lungcan.2013.02.014

. Tu C, Chen C, Hsia T, Liao W, Chen W, Hsu W. P1.03-053 Taiwan Real Word Efficacy of 1st Line EGFR TKIs Treatment in EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(11):S1971. https://doi.org/10.1016/j.jtho.2017.09.858

. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007;13(12):3731–7. https://doi.org/10.1158/1078-0432.CCR-07-0088

. Frances A. Shepherd, M.D., José Rodrigues Pereira, M.D., Tudor Ciuleanu, M.D., Eng Huat Tan, M.D., Vera Hirsh, M.D., Sumitra Thongprasert MD. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. N Engl J Med. 2005;365:687–96.

. Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol. 2005;23(1):165–74. https://doi.org/10.1200/JCO.2005.04.057

. Ricciardi S, Tomao S, de Marinis F. Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. Lung Cancer Targets Ther. 2011;2:1–9. https://doi.org/10.2147/LCTT.S10167

. Holcmann M, Sibilia M. Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol. 2015;2(4):1–10. https://doi.org/10.1080/23723556.2015.1004969

. Bethesda. Gefitinib. 2018;(Md):1–10.

. Cersosimo RJ. Gefitinib: An adverse effects profile. Expert Opin Drug Saf. 2006;5(3):469–79. https://doi.org/10.1517/14740338.5.3.469

. Araki T, Yashima H, Shimizu K, Aomori T, Hashita T, Kaira K, et al. Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol. 2012;6:407–21. https://doi.org/10.4137/CMO.S7340




DOI: https://doi.org/10.25077/jsfk.10.2.238-247.2023

Article Metrics

Abstract view : 347 times
PDF view/download : 228 times

Bookmark and Share


JSFK (Jurnal Sains Farmasi & Klinis) (J Sains Farm Klin) | p-ISSN: 2407-7062 | e-ISSN: 2442-5435

Diterbitkan oleh Fakultas Farmasi Universitas Andalas bekerjasama dengan Ikatan Apoteker Indonesia - Daerah Sumatera Barat 

      

 JSFK is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.